Servei de Bioquímica and Institut de Recerca, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Br J Nutr. 2010 Jan;103(2):153-60. doi: 10.1017/S0007114509991656. Epub 2009 Oct 13.
Disodium ascorbyl phytostanol phosphate (FM-VP4) is a synthetic compound derived from sitostanol and campestanol that has proved to be efficient as a cholesterol-lowering therapy in mice and human subjects. However, the mechanism of action of FM-VP4 remains unknown. The present study tests the ability of FM-VP4 to alter intestinal and liver cholesterol homeostasis in mice. Female C57BL/6J mice were fed either a control chow or a 2 % FM-VP4-enriched diet for 4 weeks. FM-VP4 reduced the in vivo net intestinal cholesterol absorption and plasma and liver cholesterol concentrations by 2.2-, 1.5- and 1.6-fold, respectively, compared with control mice. Furthermore, FM-VP4 also showed an impact on bile acid homeostasis. In FM-VP4 mice, liver and intestinal bile acid content was increased by 1.3- and 2.3-fold, respectively, whereas faecal bile acid output was 3.3-fold lower. FM-VP4 also increased the intestinal absorption of orally administered [3H]taurocholic acid to small intestine in vivo. Inhibition of intestinal cholesterol absorption by FM-VP4 was not mediated via transcriptional increases in intestine liver X receptor (LXR)-alpha, adenosine triphosphate-binding cassette transporter (ABC)-A1, ABCG5/G8 nor to decreases in intestinal Niemann-Pick C1-like 1 (NPC1L1) expression. In contrast, FM-VP4 up-regulated liver LXRalpha, ABCA1, ABCG5, scavenger receptor class BI (SR-BI) and hydroxymethylglutaryl coenzyme A reductase (HMGCoA-R) gene expression, whereas it down-regulated several farnesoid X receptor (FXR)-target genes such as cytochrome P450 family 7 subfamily A polypeptide 1 (CYP7A1) and Na+/taurocholate co-transporter polypeptide (NTCP). In conclusion, FM-VP4 reduced intestinal cholesterol absorption, plasma and liver cholesterol and affected bile acid homeostasis by inducing bile acid intestinal reabsorption and changed the liver expression of genes that play an essential role in cholesterol homeostasis. This is the first phytosterol or stanol that affects bile acid metabolism and lowers plasma cholesterol levels in normocholesterolaemic mice.
抗坏血酸磷酸酯(FM-VP4)是一种从植物固醇和菜油甾醇衍生而来的合成化合物,已被证明在降低小鼠和人类胆固醇方面非常有效。然而,FM-VP4 的作用机制尚不清楚。本研究测试了 FM-VP4 改变小鼠肠道和肝脏胆固醇稳态的能力。雌性 C57BL/6J 小鼠分别用对照饲料或 2% FM-VP4 强化饲料喂养 4 周。与对照组相比,FM-VP4 使体内净肠道胆固醇吸收、血浆和肝脏胆固醇浓度分别降低 2.2、1.5 和 1.6 倍。此外,FM-VP4 还对胆汁酸稳态产生影响。在 FM-VP4 小鼠中,肝脏和肠道胆汁酸含量分别增加了 1.3 和 2.3 倍,而粪便胆汁酸排出量降低了 3.3 倍。FM-VP4 还增加了体内口服[3H]牛磺胆酸在小肠的吸收。FM-VP4 抑制肠道胆固醇吸收不是通过肠肝 X 受体(LXR)-α、三磷酸腺苷结合盒转运体(ABC)-A1、ABCG5/G8 的转录增加介导的,也不是通过降低肠道 Niemann-Pick C1 样 1(NPC1L1)表达介导的。相反,FM-VP4 上调了肝脏 LXRα、ABCA1、ABCG5、清道夫受体 B 型 I(SR-BI)和羟甲基戊二酰辅酶 A 还原酶(HMGCoA-R)的基因表达,而下调了几种法尼醇 X 受体(FXR)靶基因,如细胞色素 P450 家族 7 亚家族 A 多肽 1(CYP7A1)和 Na+/牛磺胆酸盐共转运蛋白多肽(NTCP)。总之,FM-VP4 通过诱导胆汁酸肠内重吸收,降低肠道胆固醇吸收、血浆和肝脏胆固醇,并影响胆汁酸稳态,改变在胆固醇稳态中起重要作用的肝脏基因的表达。这是第一个影响胆汁酸代谢并降低正常胆固醇血症小鼠血浆胆固醇水平的植物固醇或甾醇。